公开(公告)号：US08559542B2

公开(公告)日：2013-10-15

申请号：US12863229

申请日：2009-01-21

Applicant: Ronald Rietman ,  Ying Wang

Inventor： Ronald Rietman ,  Ying Wang

IPC: H04B7/02

CPC classification number: H04B7/0851 ,  H04B7/0404 ,  H04B7/0617 ,  H04B7/0634 ,  H04B7/086

Abstract: The present invention relates to a method for communicating a signal to a first station from a second station, the stations having antenna array. For communication in bands like 60 GHz, it is advisable to carry out analog beam steering. But it is needed to compute all the beam forming weights in a single message. Then, the invention-proposes that for each signal, in the preamble, a plurality of training symbols are included, wherein during each training symbol repetition, the receiving station adjusts at least one antenna parameter of the plurality of antennas and measuring the combined signal for computing a set of antenna weights to be applied for an analog beam forming on the antenna array for receiving and/or transmitting the data field.

Abstract translation: 本发明涉及一种用于从第二站向第一站传送信号的方法，所述站具有天线阵列。 对于60 GHz频段的通信，建议进行模拟波束转向。 但是需要在单个消息中计算所有的波束形成权重。 然后，本发明提出，对于每个信号，在前导码中包括多个训练符号，其中在每个训练符号重复期间，接收站调整多个天线中的至少一个天线参数并测量组合信号 计算要应用于在天线阵列上形成的模拟波束的天线权重集合，用于接收和/或发送数据字段。

公开(公告)号：US08546377B2

公开(公告)日：2013-10-01

申请号：US12909319

申请日：2010-10-21

Applicant: Ying Wang ,  Jason T. Brewer ,  Irini Akritopoulou-Zanze ,  Stevan W. Djuric ,  Frauke Pohlki ,  Wilfried Braje ,  Ana-Lucia Relo

Inventor： Ying Wang ,  Jason T. Brewer ,  Irini Akritopoulou-Zanze ,  Stevan W. Djuric ,  Frauke Pohlki ,  Wilfried Braje ,  Ana-Lucia Relo

IPC: C07D515/00 ,  A61K31/553 ,  A61P25/00

CPC classification number: C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D498/04

Abstract: The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract translation: 本申请涉及1,2,3,4,4a，5,6,7-八氢吡嗪并[1,2-a] [1,4]苯并二氮杂，1,2,3,4,4a， 7-八氢吡嗪并[1,2-a] [1,5]苯并二氮杂，2,3,4,4a，5,6,7,11b-八氢-1H-吡啶并[3,4-d] [2]苯并氮杂， 1,2,3,4,4a，5,6,7-八氢吡嗪并[1,2-a] [1]苯并氮杂，1,2,3,4,4a，5-六氢-7H-吡嗪并[1,2 -a] [4,1]苯并氧氮杂和2,3,4,4a，5,6-六氢-1H-吡嗪并[2,1-d] [1,5]苯并氧氮杂和5,6,7,7a ，其中R 1，R 2，R 3，R 4，R 5，R 6，R 6，R 5，R 6， X1，X2，X3，X4，Y1，Y2和Y3如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。

公开(公告)号：US20130248849A1

公开(公告)日：2013-09-26

申请号：US13990832

申请日：2011-12-19

Applicant: Jerals Feldman ,  Norman Herron ,  Michael Henry Howard, JR. ,  Nora Sabina Radu ,  Vsevolod Rostovtsev ,  Kerwin D. Dobbs ,  Adam Fennimore ,  Weiying Gao ,  Weishi Wu ,  Ying Wang ,  Charles D. Mclaren

Inventor： Jerals Feldman ,  Norman Herron ,  Michael Henry Howard, JR. ,  Nora Sabina Radu ,  Vsevolod Rostovtsev ,  Kerwin D. Dobbs ,  Adam Fennimore ,  Weiying Gao ,  Weishi Wu ,  Ying Wang ,  Charles D. Mclaren

IPC: H01L51/00

CPC classification number: H01L51/0072 ,  C09K11/025 ,  C09K11/06 ,  C09K2211/1003 ,  C09K2211/1029 ,  C09K2211/1059 ,  C09K2211/185 ,  H01L51/0061 ,  H01L51/0067 ,  H01L51/0074 ,  H01L51/0085 ,  H01L51/0087 ,  H01L51/0558 ,  H01L51/5016 ,  H01L2251/5384 ,  H05B33/14

Abstract: This invention relates to a composition including (a) a dopant, (b) a first host having at least one unit of Formula I, and (c) a second host compound. Formula I has the structure where Q is a fused ring linkage having the formula In Formula I: R1 is the same or different at each occurrence and is D, alkyl, aryl, silyl, alkoxy, aryloxy, cyano, vinyl, or allyl; R2 is the same or different at each occurrence and is H, D, alkyl, or aryl, or both R2 are an N-heterocycle; R3 is the same or different at each occurrence and is H, D, cyano, alkyl or aryl; and a is the same or different at each occurrence and is an integer from 0-4.

Abstract translation: 本发明涉及包含（a）掺杂剂，（b）具有至少一个式I单元的第一主体和（c）第二主体化合物的组合物。 式I具有结构式，其中Q为具有式I的稠环键。式I中：R 1在每次出现时相同或不同，为D，烷基，芳基，甲硅烷基，烷氧基，芳氧基，氰基，乙烯基或烯丙基; R2在每次出现时相同或不同，为H，D，烷基或芳基，或两者均为N-杂环; R 3在每次出现时相同或不同，为H，D，氰基，烷基或芳基; 并且a在每次出现时相同或不同，为0-4的整数。

公开(公告)号：US08518933B2

公开(公告)日：2013-08-27

申请号：US12765034

申请日：2010-04-22

Applicant: Ying Wang ,  Jason T. Brewer ,  Irini Akritopoulou-Zanze ,  Stevan W. Djuric ,  Bhadra Shelat ,  Frauke Pohlki ,  Wilfried Braje ,  Ana-Lucia Relo

Inventor： Ying Wang ,  Jason T. Brewer ,  Irini Akritopoulou-Zanze ,  Stevan W. Djuric ,  Bhadra Shelat ,  Frauke Pohlki ,  Wilfried Braje ,  Ana-Lucia Relo

IPC: C07D515/00 ,  A61K31/553 ,  A61P25/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D471/14 ,  C07D487/14 ,  C07D491/04 ,  C07D498/04 ,  Y02E60/321

Abstract: The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2 -a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7 -octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2 -a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract translation: 本申请涉及1,2,3,4,4a，5,6,7-八氢吡嗪并[1,2-a] [1,4]苯并二氮杂，1,2,3,4,4a， 7-八氢吡嗪并[1,2-a] [1,5]苯并二氮杂，2,3,4,4a，5,6,7,11b-八氢-1H-吡啶并[3,4-d] [2]苯并氮杂， 1,2,3,4,4a，5,6,7-八氢吡嗪并[1,2-a] [1]苯并氮杂，1,2,3,4,4a，5-六氢-7H-吡嗪并[1,2 -a] [4,1]苯并氧氮杂和2,3,4,4a，5,6-六氢-1H-吡嗪并[2,1-d] [1,5]苯并氧氮杂和5,6,7,7a ，其中R 1，R 2，R 3，R 4，R 5，R 6，R 6，R 5，R 6， X1，X2，X3，X4，Y1，Y2和Y3如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。

公开(公告)号：US08513424B2

公开(公告)日：2013-08-20

申请号：US13494489

申请日：2012-06-12

Applicant: Dean A. Wacker ,  Karen A. Rossi ,  Ying Wang

Inventor： Dean A. Wacker ,  Karen A. Rossi ,  Ying Wang

IPC: C07D405/00 ,  A61K31/505

CPC classification number: C07D401/12 ,  C07D401/14

Abstract: Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA.

Abstract translation: 提供了新的化合物，它们是GPR119G蛋白偶联受体调节剂。 GPR119 G蛋白偶联受体调节剂可用于治疗，预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病进展。 这些新化合物具有结构式I或式IA。

公开(公告)号：US20130176856A1

公开(公告)日：2013-07-11

申请号：US13541984

申请日：2012-07-05

Applicant: Ying Wang ,  Sundar Subramanian ,  Xinzhou Wu ,  Junyi Li ,  Thomas J. Richardson

Inventor： Ying Wang ,  Sundar Subramanian ,  Xinzhou Wu ,  Junyi Li ,  Thomas J. Richardson

IPC: H04W74/08

CPC classification number: H04W24/00 ,  H04J3/14 ,  H04L5/0064 ,  H04L43/50 ,  H04W74/0808 ,  H04W74/0816 ,  H04W84/18

Abstract: A transmission initiation interval timing structure is used in combination with a lower layer timing structure, e.g., physical layer timing structure. A device selects a subset of packet transmission initiation intervals and then limits initiation of packet transmission to those intervals thereby reducing the potential for collisions. Packet transmission may occur outside the initiation interval in which the transmission is initiated. In some embodiments, packet transmission length is intentionally limited to sizes which can be transmitted in a fraction of the amount of time the physical layer allows a single device to continuously transmit, e.g., in an amount of time which is equal to or less than the duration of a packet transmission initiation interval. This increases the probability that multiple devices will be able to successfully transmit small packets at short intervals on a regular basis even when carrier sensing techniques are used.

Abstract translation: 传输启动间隔定时结构与较低层定时结构结合使用，例如物理层定时结构。 设备选择分组传输启动间隔的子集，然后限制分组传输的开始到那些间隔，从而减少冲突的可能性。 分组传输可能发生在传输启动的启动间隔之外。 在一些实施例中，分组传输长度被有意地限制为可以在物理层允许单个设备连续发送的时间量的一小部分中传输的大小，例如，等于或小于 分组传输启动间隔的持续时间。 这增加了即使在使用载波感测技术的情况下，多个设备将能够以短时间间隔成功地发送小分组的概率。

公开(公告)号：US08478092B2

公开(公告)日：2013-07-02

申请号：US12610375

申请日：2009-11-02

Applicant: Dongning Wang ,  Ying Wang ,  Minwei Yang

Inventor： Dongning Wang ,  Ying Wang ,  Minwei Yang

IPC: G02B6/26 ,  G02B6/00

CPC classification number: G01B9/02049 ,  G01B9/02024 ,  G01K11/3206 ,  Y10T29/49826

Abstract: A single fiber Mach-Zehnder interferometer comprises an optical fiber having a core region and a cladding surrounding the core region, and a micro-cavity having part of the cladding and the core region removed, wherein the micro-cavity is adapted to receive a light beam and separate the light beam into a first light beam that propagates through the micro-cavity in an unguided mode, and a second light beam that propagates through the core region in a guided mode.

Abstract translation: 单纤维马赫 - 策德尔干涉仪包括具有芯区域和围绕芯区域的包层的光纤，以及去除了包层和芯区域的一部分的微腔，其中微腔适于接收光 光束并将光束分离成以非导向模式传播通过微腔的第一光束，以及以引导模式传播通过核心区域的第二光束。

公开(公告)号：US08460884B2

公开(公告)日：2013-06-11

申请号：US12613385

申请日：2009-11-05

Applicant: Sharon Adler ,  Tiane Dai ,  Ying Wang ,  Mukti Patel-Chamberlin ,  Cynthia C. Nast ,  Janine LaPage ,  Nosratolah Dabir Vaziri ,  Madeleine V. Pahl

Inventor： Sharon Adler ,  Tiane Dai ,  Ying Wang ,  Mukti Patel-Chamberlin ,  Cynthia C. Nast ,  Janine LaPage ,  Nosratolah Dabir Vaziri ,  Madeleine V. Pahl

IPC: G01N33/53

CPC classification number: G01N33/6893 ,  G01N33/9406 ,  G01N2333/70571 ,  G01N2800/347

Abstract: The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for hematopoietic growth factor inducible neurokinin-1 (HGFIN), wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of renal injury or renal disease, and/or the rate of loss of renal function. In other embodiments, the invention provides a method of detecting an indicator of systemic inflammation. This method entails assaying a biological sample for HGFIN, wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of systemic inflammation. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.

Abstract translation: 在某些实施方案中，本发明提供了检测肾损伤或肾脏疾病指标的方法。 该方法需要测定用于造血生长因子诱导型神经激肽-1（HGFIN）的尿液样品，其中在升高的水平存在HGFIN表示肾损伤或肾脏疾病的存在和/或程度，和/或损失的速率 肾功能。 在其它实施方案中，本发明提供了检测全身性炎症指标的方法。 该方法需要测定HGFIN的生物样品，其中在升高的水平存在HGFIN表示全身炎症的存在和/或程度。 还提供了确定这些病症进展的方法，以及确定受试者对治疗反应的方法。

公开(公告)号：US08436341B2

公开(公告)日：2013-05-07

申请号：US12644362

申请日：2009-12-22

Applicant: Norman Herron ,  Mark A. Guidry ,  Vsevolod Rostovtsev ,  Weiying Gao ,  Ying Wang ,  Yulong Shen ,  Jeffrey A. Merlo

Inventor： Norman Herron ,  Mark A. Guidry ,  Vsevolod Rostovtsev ,  Weiying Gao ,  Ying Wang ,  Yulong Shen ,  Jeffrey A. Merlo

IPC: H01L29/08 ,  H01L35/24 ,  H01L51/00

CPC classification number: C07D471/04 ,  C07D201/00 ,  C07D471/16 ,  H01L51/0061 ,  H01L51/0072 ,  H01L51/5012 ,  H01L51/5024 ,  H01L51/5052 ,  H01L51/5072 ,  H01L2251/5384

Abstract: There is provided an organic electronic device having an anode, a hole injection layer, a photoactive layer, an electron transport layer, and a cathode. At least one of the photoactive layer and the electron transport layer includes a compound having Formula I where: R1 is the same or different and can be phenyl, biphenyl, naphthyl, naphthylphenyl, triphenylamino, or carbazolylphenyl; and one of the following conditions is met: (i) R2═R3 and is H, phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, or carbazolylphenyl; or (ii) R2 is H or phenyl; and R3 is phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, and carbazolylphenyl; When both R1 are phenyl, R2 and R3 can be 2-naphthyl, naphthylphenyl, arylanthracenyl, 9-phenanthryl, triphenylamino, or m-carbazolylphenyl.

Abstract translation: 提供了具有阳极，空穴注入层，光活性层，电子传输层和阴极的有机电子器件。 光活性层和电子传输层中的至少一个包括具有式I的化合物，其中：R 1相同或不同，可以是苯基，联苯基，萘基，萘基苯基，三苯基氨基或咔唑基苯基; 满足以下条件之一：（i）R2 = R3，为H，苯基，联苯基，萘基，萘基苯基，芳基蒽基，菲基，三苯基氨基或咔唑基苯基; 或（ii）R 2为H或苯基; 联苯基，萘基，萘基苯基，芳基蒽基，菲基，三苯基氨基和咔唑基苯基; 当R 1都是苯基时，R 2和R 3可以是2-萘基，萘基苯基，芳基蒽基，9-菲基，三苯基氨基或间 - 咔唑基苯基。

公开(公告)号：US20130053345A1

公开(公告)日：2013-02-28

申请号：US13696103

申请日：2011-05-04

Applicant: Xiang-Yang Ye ,  Dean A. Wacker ,  Jeffrey A. Robl ,  Ying Wang

Inventor： Xiang-Yang Ye ,  Dean A. Wacker ,  Jeffrey A. Robl ,  Ying Wang

IPC: C07D417/14 ,  A61K31/4545 ,  C07D513/04 ,  C07D413/14 ,  C07F9/6558 ,  A61K31/675 ,  A61K31/5377 ,  A61K31/497 ,  C07D417/12 ,  A61K31/454 ,  C07D401/14 ,  A61K31/4439 ,  A61K31/496 ,  A61P3/10 ,  A61P3/08 ,  A61P9/10 ,  A61P25/00 ,  A61P13/12 ,  A61P17/02 ,  A61P9/00 ,  A61P3/00 ,  A61P9/12 ,  A61P3/04 ,  A61P3/06 ,  A61P1/18 ,  A61P25/28 ,  A61P19/08 ,  A61P27/06 ,  A61P9/04 ,  A61P29/00 ,  A61K31/4985 ,  A61K31/513 ,  A61K31/506

CPC classification number: C07D417/14 ,  C07D401/14 ,  C07D413/14 ,  C07D417/12

Abstract: Novel compounds of structure Formula I: or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein A, D, Di, E, J, L, n, Q, R2 and R4 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

Abstract translation: 其中A，D，D，E，J，L，n，Q，R 2和R 4在本文中定义的结构式I的新型化合物或其对映异构体，非对映异构体，互变异构体，前药或其盐是GPR119G 蛋白偶联受体调节剂。 GPR119 G蛋白偶联受体调节剂可用于治疗，预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病进展。 因此，本公开还涉及包含这些新化合物的组合物以及通过使用任何这些新化合物或包含任何这些新化合物的组合物来治疗与GPR119G蛋白偶联受体的活性有关的疾病或病症的方法。